Clinical trials
Multiple Endocrine Neoplasia Type 2 clinical trials
Below are recruiting multiple endocrine neoplasia type 2 clinical trials, each written for real people, not researchers. We’re tracking 50 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07303803RecruitingPhase 2
Testing Chiglitazar for fatty liver with diabetes
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
Beijing, Beijing MunicipalityAges 18–75 - NCT06932874RecruitingPhase 4
Metformin for diabetes with heart disease
This trial tests a long-acting metformin pill in people with both type 2 diabetes and coronary heart disease. It aims to see if metformin can safely help control blood sugar in this specific group.
Beijing, Beijing MunicipalityAges 30–75 - NCT07653477RecruitingPhase 3
New diabetes drug for type 2 diabetes not well controlled with metformin
This trial tests an investigational drug called UBT251 for people with type 2 diabetes whose blood sugar is not well controlled despite taking metformin, either alone or with another diabetes medicine. The goal is to see if it can lower blood sugar levels more than a placebo.
ShanghaiAges 18–75 - NCT07659574RecruitingPhase 3
Study of UBT251 injection for type 2 diabetes not controlled by diet and exercise
This trial tests a new injected drug (UBT251) for people with type 2 diabetes who haven't been able to control their blood sugar with diet and exercise alone. It aims to see if the drug can help lower blood sugar levels safely.
Changsha, HunanAges 18–75 - NCT07083154RecruitingPhase 3
Mazdutide for type 2 diabetes with early memory problems
This study tests a new medication, Mazdutide, to see if it can slow or improve memory and thinking problems in people with type 2 diabetes and early-stage cognitive impairment. It may help by targeting blood sugar control and possibly reducing the impact of diabetes on brain function.
Changsha, HunanAges 50–75 - NCT07340320RecruitingPhase 2
CX11 tablets for type 2 diabetes
This trial tests an experimental drug called CX11 to see if it helps control blood sugar in people with type 2 diabetes who are already taking metformin. It may be an option for you if your blood sugar is not well controlled and you meet the health requirements.
Birmingham, AlabamaAges 18–75 - NCT05780905RecruitingPhase 4
Semaglutide study for brain blood flow in type 2 diabetes
This trial tests whether semaglutide changes blood flow in the brain and the brain’s “barrier” (how well the brain is protected) in people with type 2 diabetes. It may help researchers understand brain-related effects of diabetes treatment using scans and blood tests.
Seattle, WashingtonAges 40–65 - NCT07109700RecruitingPhase 2
New injectable study for type 2 diabetes
This study tests a new once-weekly injectable medication (HDM1005) for people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise or metformin alone. It aims to help lower blood sugar and may also support weight loss.
Beijing, Beijing MunicipalityAges 18–65 - NCT07807059RecruitingPhase 1
Study of HRS-4729 injection in healthy people and those with kidney problems
This study is testing a new injectable medicine (HRS-4729) to see how the body processes it in people with healthy kidneys and in those with kidney problems. If you join, you will receive a single dose and have your blood and urine checked over time to measure the drug levels.
Chengdu, SichuanAges 18–65 - NCT07775404RecruitingPhase 3
Weight loss medication for Asian adults with obesity or overweight
This study tests an investigational medication called elecoglipron for weight loss in Asian adults who are overweight or have obesity, with or without type 2 diabetes. It may help participants lose weight and improve health.
BaotouAges 18 years+ - NCT07728669Recruiting
Digital diet app for people on GLP-1 therapy
This study tests a smartphone app that gives dietary advice to people who are overweight or obese and also take a GLP-1 medication (like semaglutide) for weight or diabetes. The app will help you follow a healthy eating plan while using the medication.
AlmatyAges 21–65 - NCT07684144RecruitingPhase 3
Long-term study of a weight-loss medication for people who completed an earlier trial
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
Gilbert, ArizonaAges 18–99 - NCT07599410RecruitingPhase 2
Testing HRS9531 for Type 2 Diabetes Blood Sugar Control
This study tests whether a new tablet called HRS9531 helps people with type 2 diabetes control their blood sugar better. You would take it along with your current diabetes management (lifestyle changes or metformin) over several months.
Beijing, Beijing MunicipalityAges 18–70 - NCT07588438RecruitingPhase 4
Tirzepatide effectiveness and safety for diabetes and weight loss in Paraguay
This study tests how well and safely tirzepatide (a new injectable medication) works in real-world conditions for people with type 2 diabetes or obesity in Paraguay. The medication helps lower blood sugar and reduce weight.
AsunciónAges 18–70 - NCT07539415RecruitingPhase 1
Safety and effectiveness study of new injection in healthy adults
This study tests a new experimental injection in healthy volunteers to see if it's safe and how well the body absorbs it. Researchers will compare it with other similar treatments to understand how it works.
SeoulAges 19–64 - NCT07456774Enrolling by invitation
How long do people stay on Ozempic for diabetes (China study)
This study looks at how well people in China stick with taking Ozempic (a once-weekly injection) compared to other diabetes medicines. It helps researchers understand if this medicine is easier to keep taking long-term.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07428746RecruitingPhase 3
GLP-1 drug for bone health in older women with diabetes
This study tests whether a diabetes medication called a GLP-1 receptor agonist can help improve bone and muscle health in older women with type 2 diabetes who are at risk for osteoporosis. It aims to see if the drug can strengthen bones and prevent falls.
Atlanta, GeorgiaAges 65 years+ - NCT07347080RecruitingEarly Phase 1
Study of a new RNA-based drug for type 2 diabetes
This trial tests an experimental injection (CR059) for type 2 diabetes. It looks at safety and how the body handles different doses. You may qualify if you have had diabetes for 3 months to 5 years and are currently managing it with diet/exercise or certain diabetes pills.
Luoyang, HenanAges 18–65 - NCT07059377RecruitingPhase 3
Semaglutide to help smokers with diabetes quit
This study tests if the diabetes drug semaglutide can help people with type 2 diabetes stop smoking more easily. Participants will get either semaglutide or a placebo to see if it improves quit rates.
Ottawa, OntarioAges 18 years+ - NCT07027995Recruiting
Food and Fitness with Medicine
This study tests a program that combines nutrition counseling, online grocery support, and exercise sessions for people taking GLP-1 medications. It aims to help manage conditions like high blood pressure, diabetes, high cholesterol, kidney disease, or metabolic syndrome.
Columbus, OhioAges 18 years+ - NCT06003153RecruitingPhase 4
Gene and sugar response study with oral semaglutide
This study looks at how your genes affect your body's response to a diabetes medication called semaglutide. It may help people with slightly high blood sugar (pre-diabetes) understand why some respond better than others.
Boston, MassachusettsAges 18–65 - NCT05071898RecruitingPhase 1
Studying how genetics affect response to GLP-1 weight-loss drugs
This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.
Lancaster, PennsylvaniaAges 18–89 - NCT03883412RecruitingPhase 4
Exercise and liraglutide for type 2 diabetes
This study tests if combining exercise with a drug called liraglutide improves blood vessel health and insulin sensitivity in people with type 2 diabetes. It looks at whether these treatments work better together or alone.
Charlottesville, VirginiaAges 21–60 - NCT06894784RecruitingPhase 3
Combining two diabetes drugs with an automated insulin pump
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
Montreal, QuebecAges 18 years+
Hear when a new Multiple Endocrine Neoplasia Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple endocrine neoplasia type 2?
- Yes. Clin2 currently lists 50 recruiting multiple endocrine neoplasia type 2 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple endocrine neoplasia type 2 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple endocrine neoplasia type 2 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.